Search

Your search keyword '"Anemia -- Development and progression"' showing total 8 results
Start Over Descriptor "Anemia -- Development and progression" Topic chronic kidney failure -- development and progression
8 results on '"Anemia -- Development and progression"'

1. New Chronic Kidney Disease Data Have Been Reported by Researchers at Kaohsiung Chang Gung Memorial Hospital and Chang Gung University (WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease)

Subjects
Medical research, Medicine, Experimental, Anemia -- Development and progression, Chronic kidney failure -- Development and progression, Cancer -- Development and progression, Health
Abstract

2022 APR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in chronic kidney disease. According to news reporting from Kaohsiung City, [...]

Published
2022

2. Section 2 cardiovascular disease

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Sanofi S.A., Anemia -- Development and progression, Chronic kidney failure -- Development and progression, Hypodermic syringes, Surface active agents, Antilipemic agents, Syringes, Cardiovascular diseases -- Development and progression, Hypodermic needles, Pharmaceutical industry, Health, Maxzide (Medication)
Abstract

2A Anemias ARANESP Amgen R Erythropoiesis stimulating protein. Darbepoetin alfa 25mcg/mL, 40mcg/mL, 60mcg/mL, 100mcg/mL, 150mcg/0.75mL, 200mcg/mL, 300mcg/mL, 500mcg/mL; for IV or SC inj; preservative-free; contains albumin (human) or polysorbate 80. [...]

Published
2013

3. Section 2 cardiovascular disease

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Sanofi S.A., Anemia -- Development and progression, Chronic kidney failure -- Development and progression, Hypodermic syringes, Surface active agents, Antilipemic agents, Cardiovascular diseases -- Development and progression, Syringes, Hypodermic needles, Pharmaceutical industry, Health, Maxzide (Medication)
Abstract

2A Anemias ARANESP Amgen R Erythropoiesis stimulating protein. Darbepoetin alfa 25mcg/mL, 40mcg/mL, 60mcg/mL, 100mcg/mL, 150mcg/0.75mL, 200mcg/mL, 300mcg/mL, 500mcg/mL; for IV or SC inj; preservative-free; contains albumin (human) or polysorbate 80. [...]

Published
2013

4. Airlangga University Researchers Update Knowledge of Tropical and Infectious Diseases (C-reactive Protein and Hepcidin in Non-Dialysis Chronic Kidney Disease)

Subjects
Biochemistry -- Physiological aspects, Communicable diseases -- Development and progression, Anemia -- Development and progression, Chronic kidney failure -- Development and progression, C-reactive protein -- Physiological aspects, Health
Abstract

2021 AUG 23 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on tropical and infectious diseases. According to news reporting from Surabaya, [...]

Published
2021

5. Data on Chronic Kidney Disease Reported by Researchers at University of Porto (Hepcidin in chronic kidney disease anemia)

Subjects
Medical research, Anemia -- Development and progression, Chronic kidney failure -- Development and progression, Inflammation, Kidney diseases, Editors, Health, University of Porto
Abstract

2019 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Kidney Diseases and Conditions - Chronic Kidney Disease. According to [...]

Published
2019

6. Data on Anemia Detailed by M. Kuwahara and Co-Authors

Subjects
Anemia -- Development and progression, Hemoglobin, Chronic kidney failure -- Development and progression, Health
Abstract

'Anemia is a common complication of patients with chronic kidney disease (CKD), which not only lowers their quality of life but also potentially causes cardiovascular diseases such as congestive heart [...]

Published
2011

7. FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study

Subjects
Astellas Pharma Inc., FibroGen Inc., Medical research, Medicine, Experimental, Anemia -- Development and progression, Erythropoietin, Chronic kidney failure -- Development and progression, Glycosylated hemoglobin, Cancer -- Care and treatment, Clinical trials, Hemodialysis, Pharmaceutical industry, Business, Business, international, National Kidney Foundation
Abstract

Interim results of ongoing study presented at the National Kidney Foundation Spring Clinical Meetings SAN FRANCISCO -- FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor [...]

Published
2011

8. New Anemia Research Reported from D. Leonardis and Co-Authors

Subjects
Cholesterol, Anemia -- Development and progression, Chronic kidney failure -- Development and progression, Health
Abstract

By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators discuss new findings in Hematologic Diseases. According to news reporting originating in Reggio di Calabria, Italy, by [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results